Important Update: Mounjaro KwikPen® Device Changes Coming April 2026

05 March, 2026  |  Holy Winter - Healthcare Writer

Important Update: Mounjaro KwikPen® Device Changes Coming April 2026

IQDoctor would like to inform patients about an upcoming update to the Mounjaro® (tirzepatide) KwikPen® device, announced by Eli Lilly and Company.

From April 2026, a modified version of the Mounjaro KwikPen® will begin to enter circulation in the UK. This update includes minor visual and structural changes designed to improve usability and reduce medication waste.

Importantly, the medicine itself remains unchanged.

What Is Changing?

The updated KwikPen® has been redesigned to:

  • Reduce leftover medicine after the final dose

  • Make it clearer when the fourth and final dose has been administered

  • Improve visibility of when the pen is ready to be safely discarded

Both the original and modified versions:

  • Are disposable, multi-dose, single-patient-use pre-filled pens

  • Deliver 4 fixed 0.6mL weekly doses

  • Contain additional solution required for priming before each injection

During the transition period, patients may receive either version while existing stock is phased out.

Visual & Structural Differences

While the device functions in the same way, patients may notice:

✔ Plunger Position

The plunger sits slightly further down in the cartridge before first use.

✔ Extended Plunger Component

A new internal component extends the plunger length. This is referenced in the updated Instructions for Use (IFU).

✔ Clearer End-of-Pen Indicator

After the fourth dose, the plunger will be positioned near the end of the cartridge, clearly showing the pen is empty and ready to discard.

There are no changes to dosing, administration method, or strength availability.

GTIN and PIP codes remain unchanged, and healthcare providers will continue ordering as usual.

What This Means for IQDoctor Patients

If you are prescribed Mounjaro through IQDoctor:

  • You may receive either the original or modified KwikPen during the transition period

  • Both versions deliver the same medication and dose schedule

  • Administration remains once weekly as prescribed

What Happened to the "Golden Dose"?

Some patients previously noticed a small amount of liquid remaining in their Mounjaro KwikPen after completing four weekly doses. This was sometimes referred to informally as the "golden dose." 

It is important to clarify that the pen was always designed to deliver four fixed doses only. Any remaining liquid was included to allow for priming before each injection and was not an additional prescribed dose.

With the updated KwikPen device, the design has been modified to reduce leftover medicine and clearly indicate when the fourth and final dose has been administered. This change does not affect the strength, effectiveness, or total prescribed treatment. Patients are still receiving the full, clinically approved course of medication exactly as intended.

As always, if you have questions about your treatment, IQDoctor's clinical team is here to help.

Approved Indications

According to the Summary of Product Characteristics, Mounjaro (tirzepatide) is indicated for:

Type 2 Diabetes Mellitus

For adults with insufficiently controlled type 2 diabetes mellitus:

  • As monotherapy when metformin is inappropriate due to intolerance or contraindications

  • In addition to other medicinal products for diabetes treatment

  • As an adjunct to diet and exercise

Weight Management

As an adjunct to a reduced-calorie diet and increased physical activity for:

  • Adults with BMI ≥30 kg/m² (obesity)

  • Adults with BMI ≥27 kg/m² to <30 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes)

Eligibility for treatment is always subject to clinical assessment.

Safety & Reporting Information

As with all medicines, adverse events and product complaints should be reported.

In the UK, reports can be submitted via the MHRA Yellow Card Scheme:
www.mhra.gov.uk/yellowcard
(or search "MHRA Yellow Card" in the App Store or Google Play)

Adverse events and product complaints can also be reported directly to Lilly UK on 01256 315 000.

IQDoctor Commitment to Patient Safety

IQDoctor is a UK-registered online pharmacy. All prescriptions are reviewed by qualified clinicians, and patient safety remains our highest priority.

If you have any concerns about your medication or device, please contact our clinical support team for guidance.


Reference: Mounjaro® KwikPen® Summary of Product Characteristics. Data on File – Eli Lilly and Company. 2026.



Reviewed By

Omar El-Gohary

Omar El-Gohary

The superintendent and lead pharmacist - registration number 2059792.

Omar is passionate about developing healthcare technology to empower our patients.

Related Posts

 | 

Xmas & New Year Delivery Times

 | 

How To Salvage Your Failing New Year’s Resolution

 | 

Metro News


Tags

No Tags Available


Get the latest news